| NCT06904261 | A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants | RECRUITING | PHASE3 | 2025-10 | 2028-12 | 2027-12 |
| NCT04808505 | A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 | RECRUITING | PHASE3 | 2023-07-18 | 2027-04 | 2027-04 |
| NCT04020055 | A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | RECRUITING | PHASE3 | 2022-10-31 | 2026-12-31 | 2026-12-31 |
| NCT03911505 | ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD | RECRUITING | PHASE3 | 2020-02-13 | 2026-06 | 2026-06 |
| NCT04138277 | A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD | COMPLETED | PHASE3 | 2019-12-18 | 2024-12-31 | 2024-12-31 |
| NCT04049760 | Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease | COMPLETED | PHASE3 | 2019-10-11 | 2024-11-29 | 2024-11-29 |
| NCT03729362 | A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease | COMPLETED | PHASE3 | 2018-12-04 | 2021-01-15 | 2020-12-15 |
| NCT03500094 | Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) | COMPLETED | PHASE3 | 2018-09-27 | 2021-02-06 | 2021-02-02 |
| NCT02675465 | First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 | COMPLETED | PHASE1, PHASE2 | 2016-04 | 2024-08-20 | 2024-07-15 |
| NCT02725580 | Gene Therapy For Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease | COMPLETED | PHASE1, PHASE2 | 2016-03-09 | 2021-10-27 | 2021-10-27 |
| NCT02194985 | Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease | COMPLETED | PHASE3 | 2015-03-14 | 2019-10-23 | 2019-10-23 |
| NCT02082327 | A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers | COMPLETED | PHASE1 | 2014-03 | 2014-06 | 2014-06 |
| NCT01380743 | Drug-drug Interaction Study | COMPLETED | PHASE2 | 2011-10-31 | 2013-01-04 | 2013-01-04 |
| NCT01458119 | Open-Label Phase 3 Long-Term Safety Study of Migalastat | TERMINATED | PHASE3 | 2011-10-14 | 2016-02-17 | 2016-02-17 |
| NCT01489995 | Migalastat Food Effect Study | COMPLETED | PHASE1 | 2011-10 | 2011-12 | 2011-12 |
| NCT01218659 | Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease | COMPLETED | PHASE3 | 2011-09-08 | 2015-05-28 | 2014-05-27 |
| NCT01853852 | A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects | COMPLETED | PHASE1 | 2011-09 | 2011-12 | 2011-12 |
| NCT01730469 | Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function | COMPLETED | PHASE1 | 2011-08 | 2012-04 | 2012-04 |
| NCT01730482 | A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014) | COMPLETED | PHASE1 | 2011-08 | 2011-09 | 2011-09 |
| NCT01196871 | Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease | COMPLETED | PHASE2 | 2011-02-02 | 2012-10-09 | 2012-10-09 |
| NCT00925301 | Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease | COMPLETED | PHASE3 | 2009-10-23 | 2014-01-29 | 2012-06-12 |
| NCT00813865 | A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients | COMPLETED | PHASE2 | 2009-05-11 | 2012-05-01 | 2012-05-01 |
| NCT00875160 | A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101 | TERMINATED | PHASE1 | 2009-04 | 2009-07 | 2009-07 |
| NCT00688597 | Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease | TERMINATED | PHASE2 | 2008-12-08 | 2009-12-14 | 2009-12-14 |
| NCT00446550 | A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease | COMPLETED | PHASE2 | 2008-06-11 | 2009-08-20 | 2009-08-20 |
| NCT00526071 | Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study | TERMINATED | PHASE2 | 2007-09-17 | 2012-09-08 | 2012-09-08 |
| NCT00433147 | A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy | COMPLETED | PHASE2 | 2007-03-23 | 2008-02-19 | 2008-02-19 |
| NCT00304512 | A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease | COMPLETED | PHASE2 | 2006-09-07 | 2008-05-09 | 2008-05-09 |
| NCT00283959 | A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease | COMPLETED | PHASE2 | 2006-06-27 | 2008-05-08 | 2008-05-08 |
| NCT00283933 | A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease | COMPLETED | PHASE2 | 2006-05-09 | 2008-03-12 | 2008-03-12 |
| NCT00214500 | A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease | COMPLETED | PHASE2 | 2006-01-02 | 2008-01-29 | 2008-01-29 |